CCMH
ALXN

Cornerstone Capital Management Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$6.49M Buy
54,244
+5,883
+12% +$716K 0.05% 385
2017
Q3 		$6.78M Sell
48,361
-2,216
-4% -$301K 0.05% 361
2017
Q2 		$6.15M Buy
50,577
+11,730
+30% +$1.37M 0.05% 387
2017
Q1 		$4.71M Sell
38,847
-147
-0.4% -$19K 0.04% 477
2016
Q4 		$4.77M Sell
38,994
-3,213
-8% -$393K 0.04% 490
2016
Q3 		$5.17M Sell
42,207
-6,075
-13% -$782K 0.04% 456
2016
Q2 		$5.64M Hold
48,282
– – 0.05% 424
2016
Q1 		$6.72M Sell
48,282
-1,015
-2% -$149K 0.06% 373
2015
Q4 		$9.4M Sell
49,297
-1,239
-2% -$216K 0.08% 283
2015
Q3 		$7.9M Sell
50,536
-541
-1% -$98.7K 0.07% 306
2015
Q2 		$9.23M Buy
51,077
+4,515
+10% +$779K 0.08% 277
2015
Q1 		$8.07M Buy
46,562
+522
+1% +$94.5K 0.08% 323
2014
Q4 		$8.52M Buy
46,040
+1,821
+4% +$337K 0.09% 310
2014
Q3 		$7.33M Sell
44,219
-185
-0.4% -$30.4K 0.08% 324
2014
Q2 		$6.94M Sell
44,404
-3,706
-8% -$585K 0.08% 341
2014
Q1 		$7.32M Buy
48,110
+1,190
+3% +$189K 0.09% 315
2013
Q4 		$6.23M Sell
46,920
-1,020
-2% -$122K 0.07% 354
2013
Q3 		$5.57M Buy
47,940
+192
+0.4% +$21.1K 0.07% 371
2013
Q2 		$4.41M Buy
+47,748
New +$4.6M 0.05% 410

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cornerstone Capital Management Holdings's ALXN Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Alexion Pharmaceuticals (ALXN) stake by 12% in Q4 2017, buying an estimated $716K and bringing the position to 54,244 shares worth $6.49M. The position accounts for 0.05% of the portfolio, ranked #385.

Cornerstone Capital Management Holdings first reported a position in ALXN in Q2 2013 and has held it in 19 quarters since. The position peaked at $9.4M in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Cornerstone Capital Management Holdings held 54,244 shares of Alexion Pharmaceuticals worth $6.49M as of Q4 2017.
  • Cornerstone Capital Management Holdings bought 5,883 Alexion Pharmaceuticals shares in Q4 2017, an estimated $716K.
  • Alexion Pharmaceuticals made up 0.05% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #385 holding.
  • Cornerstone Capital Management Holdings first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 19 quarters since.
  • Cornerstone Capital Management Holdings's Alexion Pharmaceuticals position peaked at $9.4M in Q4 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.